LU86608A1 - VACCINE AGAINST ACQUIRED IMMUNODEFICITARY SYNDROME AND ANTIGENIC INTERMEDIATES FOR IMMUNOLOGICAL ASSAYS FOR SCREENING FOR THIS SYNDROME - Google Patents

VACCINE AGAINST ACQUIRED IMMUNODEFICITARY SYNDROME AND ANTIGENIC INTERMEDIATES FOR IMMUNOLOGICAL ASSAYS FOR SCREENING FOR THIS SYNDROME Download PDF

Info

Publication number
LU86608A1
LU86608A1 LU86608A LU86608A LU86608A1 LU 86608 A1 LU86608 A1 LU 86608A1 LU 86608 A LU86608 A LU 86608A LU 86608 A LU86608 A LU 86608A LU 86608 A1 LU86608 A1 LU 86608A1
Authority
LU
Luxembourg
Prior art keywords
antigenic
syndrome
protein
peptide
recombinant virus
Prior art date
Application number
LU86608A
Other languages
French (fr)
Inventor
Shiu-Lok Hu
Anthony E Purchio
Madisen Linda
Original Assignee
Oncogen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncogen filed Critical Oncogen
Publication of LU86608A1 publication Critical patent/LU86608A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/14011—Baculoviridae
    • C12N2710/14111—Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
    • C12N2710/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/14011—Deltaretrovirus, e.g. bovine leukeamia virus
    • C12N2740/14022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/14011—Deltaretrovirus, e.g. bovine leukeamia virus
    • C12N2740/14034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)
  • Management, Administration, Business Operations System, And Electronic Commerce (AREA)

Description

' , ·1Τ <~ s=.-rÄ-^>1e ' OR6 '\:-ά·ι5· " " " ' f , · ·.;·1 .'·1£; S=n\e de ia Frornete ime’.kcudie 1 J ΐΙΓ£ Gt/ATS ; -rf--Sc « : ?"i', · 1Τ <~ s = .- rÄ - ^> 1e' OR6 '\: - ά · ι5 · "" "' f, · ·.; · 1. '· 1 £; S = n \ e de ia Frornete ime'.kcudie 1 J ΐΙΓ £ Gt / ATS; -rf - Sc ":?" I

.............. LUXEMBOURG.............. LUXEMBOURG

^ —Cÿr'^ —Cÿr '

Demande de Brevet d’invention I. ReqHête QNCOGEN, 3005 First Avenue, Seattle, WA, Etats.-Unis d1 Amérique^ représentée par Monsieur ''Jean'Waxweiler , ’ 21-25 Alleë~Scfiëfîer> · ·Patent Application I. ReqHête QNCOGEN, 3005 First Avenue, Seattle, WA, United States of America ^ represented by Monsieur '' Jean'Waxweiler, ’21-25 Alleë ~ Scfiëfîer> · ·

Luxembourg.,.. ..agis saut....en .qualité-de_..mandataire________irî' ** ·.;1·“2 r --- --:.........................................Luxembourg., .. ..agis jump .... in .quality-of _ .. representative ________ irî '** ·.; 1 · “2 r --- -: ............ .............................

déposant! ce virtqt-cing septembre mil neuf cent caiatre-vingt-six_ à r ^ P— heures, au Ministère de l'Économie et des Classes Moyennes, à Luxembourg: .-1-lÿlipS^ L la présente requête pour l’obtention d'un brevet d'invention concernant: · ·depositing! this virtual September, one thousand nine hundred and twenty-six at six o'clock in the afternoon, at the Ministry of the Economy and the Middle Classes, in Luxembourg:.-1-lÿlipS ^ L the present request for obtaining an invention patent concerning: · ·

Vaccin „ contre ....le......syndrome ...immunodéf icitaire jacqui s et_inte^^^‘V;, médiaires antigéniques pour dosages immunologiques de dépis-^?Mc tage de ce syndrome. ...... ... .........M^jgÉ^r·' ^^ ................. ___ _ __ 1.Vaccine against .... the ...... syndrome ... immunodeficiency jacqui s et_inte ^^^ ‘V ;, antigenic mediaries for immunological assays of screening - ^? Mage of this syndrome. ...... ... ......... M ^ jgÉ ^ r · '^^ ................. ___ _ __ 1.

. . , 7· ’ .......... ........ ~................7..... ................” " .. . , 7 · '.......... ........ ~ ................ 7 ..... ..... ........... ”".

2. la description en langue française____________________________de l'invention en trois exemplaires: ·· 3. ---------.32 . planches de dessin, en trois exemplaires: . .¾¾ ’~- 4. la quittance des taxes versées au Bureau de l'Enregistrement à Luxembourg, le _.2 5.09.19 8 6_. M ~ 5. la délégation de pouvoir, datée de ................... ........................................... le ... .________:2. the description in French ____________________________ of the invention in three copies: ·· 3. ---------. 32. drawing boards, in three copies:. .¾¾ ’~ - 4. the receipt of the fees paid to the Luxembourg Registration Office, _.2 5.09.19 8 6_. M ~ 5. the delegation of power, dated ................... .................... ....................... the ... .________:

• » V• »V

6. le document d'ayant cause (autorisation); déciareinti en assumant la responsabilité de cette déclaration, que l't es > unenteuris i est (sont l: ’·' · ^¾¾}6. the successor document (authorization); deciareinti assuming responsibility for this statement, that the t es> unenteuris i is (are l: ’· '· ^ ¾¾}

Shiu-Lok Eu, 14128.175 Avenue NE, Redmond, Washington, E.U.Ä. .............Shiu-Lok Eu, 14128.175 NE Avenue, Redmond, Washington, E.U.Ä. .............

Purchio .AnthonvF.,2Gll llth Avenue J^t, Seattle, Washington, E.U.A. ...Purchio .AnthonvF., 2Gll llth Avenue J ^ t, Seattle, Washington, E.U.A. ...

Madisen Linda, 1516 South Massachusetts Street, Seattle, Washington, £.¾^¾^ -- I -I ni - — 2····· r »—·«»— ................................................i. » ·ί|1> __________ " ' ' 1¾¾¾¾¾¾ — · 1 .Madisen Linda, 1516 South Massachusetts Street, Seattle, Washington, £ .¾ ^ ¾ ^ - I -I ni - - 2 ····· r "- ·" "- ........... ..................................... i. "· Ί | 1> __________" '' 1¾¾¾¾¾¾ - · 1.

/ ________________________________ -- ffiég» T/ ________________________________ - ffiég »T

revendique! nn pour la susdite demande de brevet la priorité d'une (des i demande(s) de ·1 _____________________deposée(s) en (8)Etats-Unis d1 Amérique le(9)1)—25...09.. 1985;......2) .....27.03.1986 ? 3) 09.09.1986__ ^¾¾¾¾¾ um le N° (10) j· ) - 06/779,9 Ô 9 2) 06/842,984; 3 )_ numéro à suivre au nom de (11 : . C. annexe ___________________________________________________________ _____ __________________ élit:élisenti domicile pour lui (elle) et. si désigne, pour son mandataire, à Luxembourg - , - .claims! nn for the above patent application the priority of one (of i application (s) of · 1 _____________________ filed (s) in (8) United States of America on (9) 1) —25 ... 09 .. 1985 ; ...... 2) ..... 27.03.1986? 3) 09.09.1986__ ^ ¾¾¾¾¾ um N ° (10) j ·) - 06 / 779,9 Ô 9 2) 06 / 842,984; 3) _ number to follow in the name of (11:. C. appendix ___________________________________________________________ _____ __________________ elected: elected domicile for him (her) and. If appointed, for his representative, in Luxembourg -, -.

,_21r25.. Allée S chef fer, Luxembourg_______________________________ ______- (12) sollicite!nt) la délivrance d'un brevet d'invention-,pour l'objet décrit et représenté dans ies annexes susmentionnées'., _21r25 .. Allée S chef fer, Luxembourg_______________________________ ______- (12) requests! Nt) the grant of a patent for invention-, for the subject described and represented in the above-mentioned annexes'.

i r i m avec æoumement de cette délivrance à___si___________________1B--..... ..mois. (I?1 'i r i m with émouement of this delivery to ___ if ___________________ 1B --..... ..months. (I? 1 '

Le dcKasxtE' mandataire: ______UThe dcKasxtE 'representative: ______U

Π. ÎYoce—'erhal de Depo:Π. ÎYoce —'erhal de Depo:

La susdite demande de brevet d'intention a été deposet au Ministère de ’.'EcorK'inie e; des Classes Moyennes.The above application for a patent of intent has been filed with the Ministry of ’.'EcorK'inie e; of the Middle Classes.

Service de la Propriété Intelj<?$uçiki i (Tîüoqmbourc. en date du: 25. OS.1986 ' AÇjk ε / .¾ "é ,\ Pc k Ministre de ; üconvm,e e:aes CassesMv\ê-;re· * ^ à :f£..'..0JL heures ; | ; <φ1~ ^ % \ p. d.Property Service Intelj <? $ Uçiki i (Tîüoqmbourc. Dated: 25. OS.1986 'AÇjk ε / .¾ "é, \ Pc k Minister of; üconvm, ee: aes CassesMv \ ê-; re · * ^ to: f £ .. '.. 0JL hours; |; <φ1 ~ ^% \ pd

y2/V U\ jy Le chef du service de la propriété intellectuelle,y2 / V U \ jy The Head of the Intellectual Property Service,

- ksap ‘ . — 'T- ksap ‘. - 'T

2 Ε>^0010^ΚΗ^ΑΠνΈ5Α2 DEPOT ' '3 s 11 r lift jt cr lx" u.. c actumr ùu ri'-.vt ".-".gna. i »n tv-r-m- ru :: »c ..;r»k N. c^. ~-'2 '‘s^r.rr ~ϊ;>τϊ; , r^r^w 2.T:éO»ur i.'<. J; -r j ; ?«·’ —'1 Γ·37Τ«Λί.·-?· v r 1Ve; 2· v.. êti . "î -. :j: ::l ..kn < x-.rr^·.1 'CT1v2'ieiBù'Li;i>1 " ’ rr Ί.. r-τη.«Π. a_.:estse Z~ ΖέΓ- iric; >Tî«r:. e' ^r.»rr»itî 1n’a«···- . «> · - ~ · . s t e “ — -.·—.t- ;tna»a»flefnjrÆa'Bue”2 Ε> ^ 0010 ^ ΚΗ ^ ΑΠνΈ5Α2 DEPOT '' 3 s 11 r lift jt cr lx "u .. c actumr ùu ri '-. Vt" .- ". Gna. I» n tv-rm- ru :: » c ..; r »k N. c ^. ~ -'2 '' s ^ r.rr ~ ϊ;> τϊ;, r ^ r ^ w 2.T: éO» ur i. '<. J; - rj;? "· '—'1 Γ · 37Τ" Λί. · -? · vr 1Ve; 2 · v .. étti. "î -. : j: :: l ..kn <x-.rr ^ · .1 'CT1v2'ieiBù'Li; i> 1 "' rr Ί .. r-τη." Π. a_.:estse Z ~ ΖέΓ- iric ;> Tî “r :. e '^ r.” Rr ”itî 1n'a“ ··· -. “> · - ~ ·. Ste“ - -. · —.T-; tna ”a” flefnjrÆa'Bue ”

Claims (7)

1. Virus recombinant, caractérisé en ce que son génome comprend une séquence de nucléotides codant pour un épitope de virus associé à l'adénopathie (LAV)/virus de leu-5 cémie de cellules ou lymphocytes T-humains (HTLV-III), ou d'une portion antigénique de cette séquence qui est sous la commande d'une seconda séquence de nucléotides qui régule l'expression du gène de^manière qu'un peptide, ou une proté-j ine apparenté(e) à l'épitope de LAV/HTLV III soit exprimé(e) 1. dans un hôte infecté par le virus.1. Recombinant virus, characterized in that its genome comprises a nucleotide sequence coding for a virus epitope associated with lymphadenopathy (LAV) / leu-5 cemia virus of human T cells or lymphocytes (HTLV-III), or an antigenic portion of this sequence which is under the control of a second nucleotide sequence which regulates the expression of the gene such that a peptide, or a protein related to the epitope of LAV / HTLV III is expressed 1. in a host infected with the virus. 2. Virus recombinant selon la revendication 1, caractérisé en ce que la séquence des nucléotides codant pour l'épitope de LAV/HTLV III comprend la séquence du gène d'enveloppe de LAV/HTLV III ou n'importe quelle partie de 15 ce gène codant pour un peptide ou protéine antigénique.2. Recombinant virus according to claim 1, characterized in that the nucleotide sequence coding for the LAV / HTLV III epitope comprises the sequence of the LAV / HTLV III envelope gene or any part of this gene encoding an antigenic peptide or protein. 3. Virus recombinant selon la revendication 2, caractérisé en ce que la séquence des nucléotides de gène d'enveloppe comprend la séquence des nucléotides telle que représentée sur la figure 2, à partir du nucléotide numéro 20 6767 au numéro 8549, ou n'importe quelle partie de cette séquence codant pour un peptide antigénique ou une protéine antigénique.3. Recombinant virus according to claim 2, characterized in that the envelope gene nucleotide sequence comprises the nucleotide sequence as represented in FIG. 2, from nucleotide number 20 6767 to number 8549, or any which part of this sequence coding for an antigenic peptide or an antigenic protein. 4. Virus recombinant salon la revendication 1, caractérisé en ce que le peptide ou la protéine exprimé(e) 25 dans l'hôte infecté est lié(e) à un épitope d'enveloppe de LAV/HTLV III, ou n'importe quelle partie antigènique de ce virus ou du peptide ou protéine d'expression.4. Recombinant virus according to claim 1, characterized in that the peptide or protein expressed in the infected host is linked to an envelope epitope of LAV / HTLV III, or any antigenic part of this virus or of the expression peptide or protein. 5. Virus recombinant selon la revendication 4, caractérisé en ce que l'épitope d'enveloppe comprend un 30 peptide ou une protéine ayant une séquence d'aminoacides essentiellement comme représentée sur la figure 2 depuis le reste aminoacida numéro 1 au reste numéro 861, ou n'importe quelle partie antigénique de cette séquence.5. Recombinant virus according to claim 4, characterized in that the envelope epitope comprises a peptide or a protein having an amino acid sequence essentially as shown in FIG. 2 from the amino acid residue number 1 to the residue number 861, or any antigenic part of this sequence. 6. Virus recombinant selon l'une quelconque des 35 ravendicatios 1 à 5, caractérisé en ce qu'il comprend un virus comportant une enveloppe.6. Recombinant virus according to any one of 35 ravendicatios 1 to 5, characterized in that it comprises a virus comprising an envelope. 7. Virus recombinant selon la revendication 6,7. Recombinant virus according to claim 6,
LU86608A 1985-09-25 1986-09-25 VACCINE AGAINST ACQUIRED IMMUNODEFICITARY SYNDROME AND ANTIGENIC INTERMEDIATES FOR IMMUNOLOGICAL ASSAYS FOR SCREENING FOR THIS SYNDROME LU86608A1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US77990985A 1985-09-25 1985-09-25
US77990985 1985-09-25
US84298486A 1986-03-27 1986-03-27
US84298486 1986-03-27

Publications (1)

Publication Number Publication Date
LU86608A1 true LU86608A1 (en) 1988-04-05

Family

ID=27119638

Family Applications (1)

Application Number Title Priority Date Filing Date
LU86608A LU86608A1 (en) 1985-09-25 1986-09-25 VACCINE AGAINST ACQUIRED IMMUNODEFICITARY SYNDROME AND ANTIGENIC INTERMEDIATES FOR IMMUNOLOGICAL ASSAYS FOR SCREENING FOR THIS SYNDROME

Country Status (4)

Country Link
BE (1) BE905492A (en)
FR (1) FR2593519B1 (en)
LU (1) LU86608A1 (en)
PH (1) PH26855A (en)

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE58011B1 (en) * 1983-05-27 1993-06-16 Texas A & M Univ Sys Method for producing a recombinant baculovirus expression vector
IL76082A (en) * 1984-08-22 1991-07-18 Us Health Molecular clones of the genome of htlv-iii and a process for the preparation thereof
US9328391B1 (en) * 1984-08-22 2016-05-03 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Cloning and expression of HIV-1 DNA
GB8501473D0 (en) * 1985-01-21 1985-02-20 Pasteur Institut Cloned dna sequences
ES8705522A1 (en) * 1984-10-18 1987-05-01 Pasteur Institut Gag antigen and its use for the detection of lav infection and in immunogenic compositions
CA1341482C (en) * 1984-10-31 2005-05-10 Paul A. Luciw Process for preparing fragments of aids-associated retroviruses
AU600658B2 (en) * 1984-12-24 1990-08-23 Genentech Inc. Molecularly cloned acquired immunodeficiency syndrome polypeptides and their methods of use
US4774175A (en) * 1985-03-01 1988-09-27 Centocor, Inc. Immunochemical methods for the detection of antibody against HTLV-III
DE3650011T2 (en) * 1985-04-08 1994-11-17 Genetic Systems Corp EXPRESSION AND DIAGNOSIS WITH GAG-CODED PEPTIDES THAT ARE IMMUNOLOGICALLY REACTIVE WITH ANTIBODIES AGAINST LAV.
NZ215867A (en) * 1985-04-19 1989-10-27 Hoffmann La Roche Aids envelope protein, dna vectors and method of production
FR2586427B1 (en) * 1985-08-20 1988-12-09 Pasteur Institut NUCLEOTIDE AND POLYPEPTIDE SEQUENCES FROM VISNA VIRUS AND THEIR APPLICATION TO DIAGNOSTIC TESTS AND THE PRODUCTION OF IMMUNOGENIC COMPOSITIONS

Also Published As

Publication number Publication date
FR2593519A1 (en) 1987-07-31
FR2593519B1 (en) 1994-01-07
BE905492A (en) 1987-03-25
PH26855A (en) 1992-11-16

Similar Documents

Publication Publication Date Title
US6395306B1 (en) Bee venom protein and gene encoding same
Ho et al. Another discontinuous epitope on glycoprotein gp120 that is important in human immunodeficiency virus type 1 neutralization is identified by a monoclonal antibody.
Kilmartin et al. Amino-acid replacements in horse haemoglobin
Frangione et al. Structural studies of human γG-myeloma proteins of different antigenic subgroups and genetic specificities
RU2020135968A (en) T-CELL RECEPTORS AND MODIFIED CELLS THAT EXPRESS
Walter et al. Molecular cloning and sequence of cDNA encoding polyoma medium tumor antigen-associated 61-kDa protein.
Birkedal-Hansen et al. Proteins of the periodontium: Characterization of the insoluble collagens of bovine dental cementum
WO1999010364A1 (en) Follistatin-3
NZ508381A (en) Antibodies, antagonists and agonists of the death domain containing receptor 5 (DR5)
PE64396A1 (en) INTERLEUKIN 1 RECEIVER ACCESSORY PROTEIN
IL152507A0 (en) Methods and compositions for impairing multiplication of hiv-1
CN1610697A (en) E type hepatitis virus monoclonal antibody or its conjugated active fragment and use thereof
EP3541839A1 (en) Methods of treating obesity with anti-angptl8 antibodies
LU86608A1 (en) VACCINE AGAINST ACQUIRED IMMUNODEFICITARY SYNDROME AND ANTIGENIC INTERMEDIATES FOR IMMUNOLOGICAL ASSAYS FOR SCREENING FOR THIS SYNDROME
CN1220699A (en) Antibodies against interferon alpha/beta receptor
JP2014525439A (en) Natriuretic polypeptide
JPS62285792A (en) Vaccine for zoster virus
FI111050B (en) Process for Preparation of Multiple Sclerosis Cerebral Spinal Cord Fluid
Te Piao King et al. Structural studies of a hornet venom allergen antigen 5, D0] 112 V and its sequence similarity with other proteins
KR102215175B1 (en) Mimetic peptides
EA015272B1 (en) Method of treatment of a disease
Burns et al. Functional role of a consensus peptide which is common to α‐, β‐, and γ‐tubulin, to actin and centractin, to phytochrome A, and to the TCP1α chaperonin protein
WO2004016647A3 (en) Fragments of proinsulin c-peptide
Sánchez et al. DmFoxF, a novel Drosophila fork head factor expressed in visceral mesoderm
WO2021236045A1 (en) Vaccine for prevention of and/or immunization against sars-cov-2